Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Aimaz Afrough, MD, Amy Sidorski, CRNP, Roberto Salvatori, MD, Ivan Borrello, MD

Blood (2016) 128 (22): 5640.

https://doi.org/10.1182/blood.V128.22.5640.5640

Published: 2016

Journal Articles

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Kimberly A Noonan, PhD MPH, Lakshmi Rudraraju, MS, Valentina Hoyos, MD, Eric Lutz, PhD, Ivan Borrello, MD

Blood (2016) 128 (22): 4552.

https://doi.org/10.1182/blood.V128.22.4552.4552

Published: 2016

Journal Articles

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Laura K Schoch, MS, CRNP, Ivan Borrello, MD, Ephraim J. Fuchs, MD, Javier Bolanos-Meade, MD, Jeffrey Sean Huo, MD PhD, Ivana Gojo, MD, Nina Wagner-Johnston, MD, Gabrielle T Prince, MD, Shannon R. McCurdy, MD, B. Douglas Smith, MD, Amy E. DeZern, MD MHS, Margaret M. Showel, MD, David Loeb, MD PhD, Aziza T. Shad, MD, Richard J Jones, MD, Richard F. Ambinder, MD PhD, Douglas Gladstone, MD

Blood (2016) 128 (22): 4571.

https://doi.org/10.1182/blood.V128.22.4571.4571

Published: 2016

Journal Articles

Marrow Infiltrating Lymphocytes and Vaccines in Myeloma

Ivan Borrello, MD

Blood (2016) 128 (22): SCI-35.

https://doi.org/10.1182/blood.V128.22.SCI-35.SCI-35

Published: 2016

Journal Articles

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Philippe Armand, MD PhD, Stephen M. Ansell, MD PhD, Alexander M. Lesokhin, MD, Ahmad Halwani, MD, Michael M. Millenson, MD, Stephen J. Schuster, MD, John Timmerman, MD, Ivan Borrello, MD, Martin Gutierrez, MD, Emma C. Scott, MD, Deepika Cattry, MSc, CCRP, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD

Blood (2014) 124 (21): 289.

https://doi.org/10.1182/blood.V124.21.289.289

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Kimberly Noonan, PhD MPH, Carol Ann Huff, Amy Sidorski, NP, Anna Ferguson, RN, Lakshmi Rudraraju, MS, Andrea Casildo, BS, Ivan Borrello, MD

Blood (2014) 124 (21): 2137.

https://doi.org/10.1182/blood.V124.21.2137.2137

Published: 2014

Journal Articles

CD4+CD25+ Marrow Infiltrating Lymphocytes in Myeloma Patients Display an Activated Phenotype and Lack Suppressive Function.

Kimberly A. Noonan, MPH, Stephanie Mgebroff, BS, Paolo Serafini, PhD, Kristen Meckel, BS, Mark Bonyhadi, PhD, Ivan Borrello, MD

Blood (2006) 108 (11): 1741.

https://doi.org/10.1182/blood.V108.11.1741.1741

Published: 2006

Journal Articles

Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity.

Ivan Borrello, MD, Anna Ferguson, RN, Carol Ann Huff, MD, Shirley George, BS, Barbara Biedryzcki, CRNP, David Cornblath, MD, Vinay Chaudhry, MD

Blood (2006) 108 (11): 3528.

https://doi.org/10.1182/blood.V108.11.3528.3528

Published: 2006

Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD

Blood (2006) 108 (11): 3579.

https://doi.org/10.1182/blood.V108.11.3579.3579

Published: 2006

NARROW

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Marrow Infiltrating Lymphocytes and Vaccines in Myeloma

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

CD4+CD25+ Marrow Infiltrating Lymphocytes in Myeloma Patients Display an Activated Phenotype and Lack Suppressive Function.

Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity.

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only